Erasca
ERAS | NASDAQ
$15.11
-$0.55 (-3.51%)
At close: Nov 16, 2026, 4:00 PM ET
$15.11
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Erasca Company Profile
Company profile explainedCompany Profile
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer |
| David Chacko | Chief Financial Officer & Chief Business Officer |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary |
| Lisa Tesvich-Bonora | Chief People Officer |
| Nik Chetwyn | Chief Operating Officer |
| Alison Tjosvold Milhous | Senior Vice President of Accounting |
| Brian L. Baker | Senior Vice President of Finance |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director |
| Robert Shoemaker | Chief Scientific Officer |
| Shannon Morris | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 12, 2026 | 3 | Filing |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 8-K | Current Report |
Erasca
| Country | United States |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Jonathan E. Lim |
Contact Details
3115 Merryfield Row San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | ERAS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001761918 |
| CUSIP Number | 29479A108 |
| ISIN Number | US29479A1088 |
| SIC Code | 2834 |
Recent News
- 17 hours ago / globenewswire.comErasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
- 13 days ago / globenewswire.comTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
- 14 days ago / globenewswire.comErasca to Present at Upcoming Conferences in November
- 1 month ago / seekingalpha.comErasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
- 2 months ago / globenewswire.comPropanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
- 2 months ago / globenewswire.comPropanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
- 2 months ago / seekingalpha.comErasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / globenewswire.comAttention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
- 2 months ago / globenewswire.comErasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- 2 months ago / globenewswire.comErasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Add to Watchlist
Select watchlists to add or remove ERAS